X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Subject expert committee asked Hetero Biopharma to submit some more documents, which had approached the drug authority to launch a generic version of the Sputnik Light vaccine made from the First Dose Ad26 for the treatment of Covid-19.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Molnupiravir is an investigational medicine developed by US based pharma firm Merc used to treat SARS-CoV-2 infection. In India, Merck Pharma Company had signed licensing agreements with various Indian pharma firms like Cipla, Dr Reddy’s, Emcure, Hetero labs and Sun Pharma.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2021
Details:
Authorization will enable doctors to use the generic drug Tocilizumab for the treatment of Covid-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or ECMO.
Lead Product(s): Tocilizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Tocira
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2021
Details:
The Russia Direct Investment Fund had entered into an agreement with Hetero to produce over 100 million doses of Russia's Covid-19 vaccine Sputnik V in India.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
The SEC has asked the company to study and monitor the Sputnik V's immunogenicity on days 21, 24, and 48 of the trial. The company was also asked by the panel to “study and assess neutralising antibodies and gamma interferon,” says the minute of the meeting.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
